We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...

There was some good news in the clinical sphere for Gilead Sciences ( GILD 2.74%) on Thursday, and this drove its stock price ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Since my last article, Gilead Sciences ... I'll present an analysis of the sales of its HIV and oncology franchises, the successes and failures in the development of its rich portfolio of next ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Gilead Sciences Inc.’s stock climbed 3% early Thursday after the company said its twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, building the case for ...

Before you buy stock in Gilead Sciences, consider this ... Moving to the liver disease portfolio on Slide 11. Sales were up ...

Our analysis of options history for Gilead Sciences GILD revealed 10 unusual ... with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought ...

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...

IBBQ is a relatively new US biotech ETF that competes with established peers like IBB and XBI. Read why I don't recommend ...

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...

There was some good news in the clinical sphere for Gilead Sciences (NASDAQ ... endpoints for preventing the disease. An interim analysis of the study found that the drug reduced new infections ...